Brief: Celltrion Inc Has Applied To European Medicines Agency For Phase 3 Clinical Trial Of Ct-P55, Biosimilar To Novartis' Cosentyx To Treat Plaque Psoriasis
14/10/2024 07:30
Oct 14 (Reuters) - Celltrion Inc 068270.KS :
* CELLTRION INC; HAS APPLIED TO EUROPEAN MEDICINES AGENCY
FOR
PHASE 3 CLINICAL TRIAL OF CT-P55, BIOSIMILAR TO NOVARTIS'
COSENTYX TO TREAT PLAQUE PSORIASIS
Source text for Eikon: ID:
Further company coverage: 068270.KS
(Reporting by Jack Kim)
((jack.kim@thomsonreuters.com;))
Recent news on Celltrion
See all newsBrief: Celltrion Inc To Acquire 100 Billion Won Worth Of Own Shares
Brief: Celltrion Q1 Operating. Profit 322 Billion Won, Up 115% Y/Y
Brief: Celltrion To Cancel 100 Billion Won Treasury Shares
Brief: Celltrion Plans Phase 3 Clinical Trials For Keytruda Biosimilar With 220 Patients
Brief: Celltrion To Buy 100 Billion Won Of Own Shares